Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4131755 | 0.95 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3PDE4ANMT1 | |
| SCHEMBL2901823 | 0.91 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2903523 | 0.90 | PDE4A (0.47) | SLC6A2SLC6A4SLC6A3PDE4ANMT1 | |
| Hydrochloric Acid SCHEMBL2908528 | 0.90 | PDE4A (0.47) | SLC6A2SLC6A4SLC6A3PDE4ANMT1 | |
| SCHEMBL2905407 | 0.89 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3PDE4ANMT1 | |
| SCHEMBL2902564 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3PDE4ANMT1 | |
| Hydrochloric Acid SCHEMBL5801370 | 0.80 | MAPT (0.42) | SLC6A2SLC6A4SLC6A3PDE4APDE4B | |
| SCHEMBL2909468 | 0.80 | PDE4A (0.45) | SLC6A2SLC6A4SLC6A3PDE4APDE4B | |
| SCHEMBL2901842 | 0.80 | PDE4D (0.38) | SLC6A2SLC6A4SLC6A3PDE4ANMT1 | |
| Oxalic Acid SCHEMBL2902724 | 0.78 | PDE4A (0.44) | SLC6A2SLC6A4SLC6A3PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | claimed |
| EP-1888528-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-02-20 | — | — | EP | claimed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | claimed |
| WO-2006135828-A2 | TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | WO | claimed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| EP-1888528-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2006135828-A2 | TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135828-A2 | TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE4B | SLC6A2 2176/4885SLC6A4 1190/4885SLC6A3 732/4885 |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE4B | SLC6A2 2176/4885SLC6A4 1190/4885SLC6A3 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.